Cases & Deals

King Pharmaceuticals obtains FTC clearance for $1.6 acquisition of drugmaker Alpharma

Clients King Pharmaceuticals, Inc.

Jones Day represented King Pharmaceuticals, Inc. as antitrust counsel in its $1.6 billion acquisition of New Jersey drugmaker Alpharma Inc., a leading developer and seller of pharmaceutical products for the treatment of pain. The transaction was cleared by the Federal Trade Commission after a Second Request and consent agreement whereby King agreed to divest KADIAN® to Actavis for $127.5 million. The parties persuaded the FTC to permit King to retain both Remoxy and Embeda, products in development for the abuse-deterrent, round-the-clock treatment of moderate to severe chronic pain. King was also permitted to retain Avinza, indicated for the round-the-clock treatment of moderate to severe chronic pain.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.